Abstract：
UNASSIGNED: Guillain-Barré syndrome (GBS) is a group of acute immune-mediated disorders in the peripheral nervous system. Both infectious and noninfectious factors are associated with GBS, which may act as triggers of autoimmune responses leading to neural damage and dysfunction.
UNASSIGNED: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vaccines as well as flaviviruses have been associated with GBS, although a robust conclusion has yet to be reached. Immunomodulatory treatments, including intravenous immunoglobulins (IVIg) and plasma exchange (PE), have long been the first-line therapies for GBS. Depending on GBS subtype and severity at initial presentation, the efficacy of IVIg and PE can be variable. Several new therapies showing benefits to experimental animals merit further investigation before translation into clinical practice. We review the state-of-the-art knowledge on the immunopathogenesis of GBS in the context of coronavirus disease 2019 (COVID-19). Immunomodulatory therapies in GBS, including IVIg, PE, corticosteroids, and potential therapies, are summarized.
UNASSIGNED: The association with SARS-CoV-2 remains uncertain, with geographical differences that are difficult to explain. Evidence and guidelines are lacking for the decision-making of initiating immunomodulatory therapies in mildly affected patients or patients with regional subtypes of GBS.
UNASSIGNED: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vaccines as well as flaviviruses have been associated with GBS, although a robust conclusion has yet to be reached. Immunomodulatory treatments, including intravenous immunoglobulins (IVIg) and plasma exchange (PE), have long been the first-line therapies for GBS. Depending on GBS subtype and severity at initial presentation, the efficacy of IVIg and PE can be variable. Several new therapies showing benefits to experimental animals merit further investigation before translation into clinical practice. We review the state-of-the-art knowledge on the immunopathogenesis of GBS in the context of coronavirus disease 2019 (COVID-19). Immunomodulatory therapies in GBS, including IVIg, PE, corticosteroids, and potential therapies, are summarized.
UNASSIGNED: The association with SARS-CoV-2 remains uncertain, with geographical differences that are difficult to explain. Evidence and guidelines are lacking for the decision-making of initiating immunomodulatory therapies in mildly affected patients or patients with regional subtypes of GBS.
摘要：
■格林-巴利综合征（GBS）是一组急性免疫介导的外周神经系统疾病。感染和非感染因素都与GBS相关，这可能是导致神经损伤和功能障碍的自身免疫反应的触发因素。
■严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）及其疫苗以及黄病毒与GBS有关，尽管尚未得出有力的结论。免疫调节治疗,包括静脉免疫球蛋白（IVIg）和血浆置换（PE），长期以来一直是GBS的一线疗法。根据初始演示时的GBS亚型和严重性，IVIg和PE的功效可以是可变的。在转化为临床实践之前，几种对实验动物有益的新疗法值得进一步研究。我们回顾了2019年冠状病毒病（COVID-19）背景下GBS免疫发病机制的最新知识。GBS中的免疫调节疗法，包括IVIg,PE,皮质类固醇,和潜在的治疗方法，是总结的。
■与SARS-CoV-2的联系仍然不确定，地理差异很难解释。在轻度受影响的患者或具有区域性GBS亚型的患者中，缺乏启动免疫调节疗法的决策的证据和指南。
■严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）及其疫苗以及黄病毒与GBS有关，尽管尚未得出有力的结论。免疫调节治疗,包括静脉免疫球蛋白（IVIg）和血浆置换（PE），长期以来一直是GBS的一线疗法。根据初始演示时的GBS亚型和严重性，IVIg和PE的功效可以是可变的。在转化为临床实践之前，几种对实验动物有益的新疗法值得进一步研究。我们回顾了2019年冠状病毒病（COVID-19）背景下GBS免疫发病机制的最新知识。GBS中的免疫调节疗法，包括IVIg,PE,皮质类固醇,和潜在的治疗方法，是总结的。
■与SARS-CoV-2的联系仍然不确定，地理差异很难解释。在轻度受影响的患者或具有区域性GBS亚型的患者中，缺乏启动免疫调节疗法的决策的证据和指南。
